While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...

Customers looking for an mRNA therapeutic partner should prioritize operational excellence and choose flexible CDMOs.

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

Researchers at the University of Cologne have found that mRNA-based COVID-19 vaccines have a lasting impact on the innate ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Researchers at the University of Cologne and University Hospital Cologne have determined that the novel mRNA-based COVID-19 ...

RNA vaccines were first developed years ago to target cancers and now they're really starting to show promise.

Researchers have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against potential ...

A genetic mutation in horses that would typically halt protein production has become a molecular asset. Researchers at Johns ...